Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CRTH2-IN-1

Catalog No: tcsc0035127

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Specifications

CAS No:
926661-54-3

Formula:
$C_{21}H_{21}FN_2O_4S$

Pathway:
GPCR/G Protein

Target:
Prostaglandin Receptor

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
Ramatroban analog

Observed Molecular Weight:
416.47

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CRTH2-IN-1 (Ramatroban analog) is a selective **prostaglandin D2 receptor DP2** (**CRTH2**) antagonist with an IC_{50} of 6 nM in a human DP2 binding assay.

IC50 & Target: IC50: 6 nM (hDP2, CRTH2), 1 μM (hDP1)[1]

In Vitro: CRTH2-IN-1 (Ramatroban analog, Compound 5) is a novel prostaglandin D2 receptor DP2 (CRTH2) antagonist with an IC_{50} of 7 nM in a human whole blood eosinophil shape change assay (hESC). CRTH2-IN-1 (Ramatroban analog) is a novel tricyclic antagonist of the prostaglandin D2 receptor DP2 (CRTH2) with efficacy in a murine model of allergic rhinitis. Human prostaglandin D1 receptor (hDP1) binding is performed using ^{3}H-PGD2 and human platelet membranes. Human thromboxane receptor (hTP) binding performed using human platelet membranes and ^{3}H-SQ-29,548. Human prostacyclin receptor (hIP) binding perfomed using hIP/293 membranes and ^{3}Hiloprost. CRTH2-IN-1 inhibits hDP1 binding with an IC_{50} of 1μM. CRTH2-IN-1 inhibits hTP and hIP binding with IC_{50}s of >100 μM. CRTH2-IN-1 inhibits human CYP isoforms CYP3A4, CYP 2C9 and CYP2D6 with IC_{50}s of 7, 5 and >30 μM, respectively[1].